Genetic Evidence for Early Divergence of Small Functioning and Nonfunctioning Endocrine Pancreatic Tumors: Gain of 9Q34 Is an Early Event in Insulinomas1
[CANCER RESEARCH 61, 5186–5192, July 1, 2001] Genetic Evidence for Early Divergence of Small Functioning and Nonfunctioning Endocrine Pancreatic Tumors: Gain of 9Q34 Is an Early Event in Insulinomas1 Ernst J. M. Speel,2 Alexander F. Scheidweiler, Jianming Zhao, Claudia Matter, Parvin Saremaslani, Ju¨rgen Roth, Philipp U. Heitz, and Paul Komminoth3 Department of Molecular Cell Biology, University of Maastricht, Research Institute Growth and Development, 6200 MD Maastricht, The Netherlands [E. J. M. S.], Department of Pathology [A. F. S., J. Z., C. M., P. S., P. U. H., P. K.], and Division of Cell and Molecular Pathology [J. R., P. K.], University of Zurich, 8091 Zurich, Switzerland ABSTRACT fields), and/or exhibit Յ2% Ki-67 positive cells. Most insulinomas fall into this category, as do nonfunctioning (micro)adenomas that are The malignant potential among endocrine pancreatic tumors (EPTs) a rather common finding in carefully examined postmortem pancre- varies greatly and can frequently not be predicted using histopathological ases (4). EPTs that are Ͼ2 cm or show angioinvasion, higher numbers parameters. Thus, molecular markers that can predict the biological behavior of EPTs are required. In a previous comparative genomic hy- of mitoses, or percentages of Ki-67 positive cells are at risk of bridization study, we observed marked genetic differences between the malignancy. They include many of the functioning tumors other than various EPT subtypes and a correlation between losses of 3p and 6 and insulinomas. gains of 14q and Xq and metastatic disease. To search for genetic alter- Our understanding of the molecular mechanisms underlying the ations that play a role during early tumor development, we have studied tumorigenesis of EPTs is still scarce.
[Show full text]